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Introduction: Infection with Human papillomavirus (HPV) has been reported as one of the most pre-
valent agent sexually transmitted diseases, but its true prevalence in men is not precisely known, mainly
due to the near absence of symptoms. Moreover, few studies evaluating the post-vaccination immune
response have been performed to date in men, hence the hypotheses tested in this study can be
important to enable a better understanding of both the immunopathogenesis and the response to vac-
cination in HIV-infected patients, and to help in the elaboration of strategies of vaccination against HPV
in the HIV-infected population.
Objectives: To analyze the speciﬁc response to antigens of HPV vaccine in HIV-infected men.
Methods: A total of 25 HIV-infected male patients who met the inclusion criteria during the data col-
lection period were vaccinated; however, six (30%) had anti-HPV at baseline, and were not considered
further in the analysis. Therefore, 19 HIV-infected individuals were included in the study, along with ﬁve
healthy, HPV-seronegative controls.
Results: Patients infected with HIV-1 were subdivided into two groups, A and B, according to their T CD4
cells count at the time of vaccination, namely: Group A: CD44500; Group B: CD4o500. The proportion
of seroconversion after immunization with three doses of a bivalent anti-HPV vaccine was 92%.
Conclusion: HIV-infected patients as well as HIV negative controls responded to anti-HPV vaccination,
regardless of their T CD4 cells count and HIV plasma viral load. These results demonstrate that anti-HPV
immunization in HIV-infected males is effective and should be encouraged, thus helping to decrease the
risk of infection, mortality and morbidity of diseases associated with HPV in men.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Human papillomavirus (HPV) infections rank among the most
common virus sexually transmitted diseases worldwide [1]; it is
an epitheliotropic virus, characterized by its icosahedral, non-
encapsulated form, with a diameter of 50 nm, and includes as its
genetic material a molecule of double-stranded circular DNA with
approximately eight thousand base pairs [2]. To date, more than
200 types of human HPV have been described and classiﬁed intoB.V. This is an open access article u
igation in Dermatology and
valho Aguiar 500, 3rd Floor,
94; fax: þ55 11 3081 7190.
tes),high and low risk subgroups; there are 45 potentially oncogenic
types infecting the anogenital region [3].
HPV escapes recognition by the immune system by not causing
cell lysis and not inducing a local inﬂammation [4]. In its infection
cycle there is no viremia, and a very low amount of viral protein is
expressed; also, the virus is not cytolytic. Thus, there is no sig-
naling to the immune system to activate the innate response, as
well as a delay in the adaptive response [1], leading to an immune
dysfunction, with a decrease in the number of antigen-presenting
cells (APCs) and T-cell lymphocytes. Immune surveillance is
impaired, due both to a deﬁcient presentation of antigens and to a
reduced effecter phase of T-lymphocyte activation and antibody
production [5].
Anti-HPV vaccine was the result of the mastering of the key
technologies that are capable of producing virus-like (VLP) parti-
cles. Recombinant DNA was used to generate VLPs able to mimicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bodies. Today there are two types of vaccines commercially
available: Cervarix s (GlaxoSmithKline Biologicals website) con-
taining VLPs (Virus Like Particle) types 16 and 18, Gardasils
(Merck Dohme Shape, Whitehouse Station, New Jersey) containing
VLPs of types 6, 11, 16 and 18. Both vaccines contain an adjuvant
aluminum salt that precipitates VLP allowing a more slowly
release of the antigen [6,7]. More recently, a prophylactic nive-
valent HPV (types 6/11/16/18/31/33/45/52/58) VLP (9vHPV) vac-
cine in young men 16–26 years of age in comparison to young
women 16–26 years of age showed safety and immunogenetic [8].
In women with immunodeﬁciency, iatrogenic or acquired, the
prevalence of HPV-associated lesions is higher than in immuno-
competent individuals [9]. HIV-seropositive subjects experience an
increased infection rate with a high number of relapse after
treatment and an accelerated development of HPV-associated
cancer [10,11]. In HIV-infected men, the prevalence of HPV in the
genital area is 18.2% while that in the anus is 59.3% [12,13].
Besides the speciﬁc response to vaccine antigens, we analyzed
the anti-HPV immune response from HIV-1-infected men in dif-
ferent strata of immune deﬁciency. The hypothesis was tested by
stratiﬁcation according to the number of T CD4þ lymphocytes, in
an attempt to assess the count range with the highest probability
of vaccine response. The degree of vaccine response in HIV-
infected patients may indicate which patients have a greater
potential for in vivo vaccine response.Material and methods
In total, 450 HIV-infected individuals have been in follow-up at
our outpatient service for the last 25 years. Among them, 300
subjects are males, 56 of whom aged 18–45 years and were seen in
the Clinic during the study. These patients underwent a screening
to check for the presence of HPV in oral samples, previously
published elsewhere [14]; eight tested positive for HPV and 23 had
other exclusion criteria and were not vaccinated. Therefore, in this
study, 25 patients satisﬁed the inclusion criteria, were invited and
agreed to participate, all of them were men who make sex with
men. Five HIV-negative control subjects were tested for HIV
infection and submitted to an oral cleansing prior to vaccination.
Patients and controls were recruited from October 2012 to Feb-
ruary 2013. The Ethical Board of Hospital das Clínicas approved the
clinical study; it is registered at the clinical trial identiﬁer
(NCT02236234).
Subject population
HIV-1-infected men aged 18–45 years old were invited to
participate, regardless acquisition mode of transmission. We
selected two groups according to the updated outpatient records:
nine had T-CD4 cells counts above 500 cells/mL whereas 16 had T-
CD4 cells counts below 500. Exclusion criteria included other
types of immunedeﬁciencies, such as renal failure or hepatic
malignancies, autoimmune diseases, immunosupressive medica-
tions, or other vaccination within the last 2–3 weeks. All patients
gave informed consent, which contained information about the
study. After agreeing to sign the term, they answered a ques-
tionnaire containing information on socio-behavioral, presence or
history of sexually transmitted diseases, HIV viral load, CD4þT
cells count and time of the ﬁrst HIV testing.
Vaccine
Cervarixs (GlaxoSmith-Kline, Brentford, England, a bivalent
human papillomavirus vaccine (types 16 and 18), is a recombinantprotein virus-like particle. It was administered by intramuscular
injection 0.5 mL at 0, 4 and 24 weeks. The primary immunogeni-
city endpoint was determined three weeks after the third
vaccination dose.
Design study
Twenty-ﬁve HIV-infected patients who met the inclusion cri-
teria during data collection period were analyzed and classiﬁed as
follows: All were vaccinated; however, six (24%) had anti-HPV
antibodies at baseline, and were not considered further in the
analysis. Therefore, 19 HIV-infected individuals were described in
the study (nine patients with T CD4 o500 cells/mm³ and 10
patients with CD4Z500 cells/mm³). Control group was made up
of ﬁve healthy adults who were negative for HIV and HCV
infections.
Laboratory methods
Samples were collected by venipuncture from the peripheral
blood of research subjects and processed in tubes containing 5 mL
of gel; the tubes were centrifuged at 2000xg at a room with a
temperature of 15 °C for 15 min. Two aliquots of 500 ml of serum
were stored at 80 °C in order to perform the analysis.
HPV serology
Presence of IgG antibodies to HPV 16 and 18 in the sera samples
wasdetected using a type speciﬁc ELISA using L1VLPs from S. cere-
visiae (kindly provided by Dr Ian Frazer, Univ of Queensland,
Woolongaba, AU). Fifty microliters of 0.03 mg/ml of each VLP were
used to coat the ELISA plates overnight at 4 °C. From every two
wells coated with VLP, one was coated with PBS, pH 7.2. Plates were
then washed once with PBST (0.02% Tween in PBS pH7.2) and
blocked with 100 ml of BSA blocking solution (1.5% bovine serum
Albumin in PBS) for 2 h. After the blocking step, plates were washed
twice with PBST. Sera and control samples, diluted 1:50 with a
solution of 5% fat free milk powder, 0.1% BSA in PBST, were tested in
duplicate and incubated at 37 °C for one hour. Plates were washed
ﬁve times with PBST and tested with horseradish peroxidase con-
jugated with anti-human IgG (TagoImmunobiologicals, USA) at
appropriated dilutions. Following 45 min of incubation at 37 °C, the
plates were washed 5 times with PBST and 50 microliters of ABTS
solution (0.05% 2,20-Azino Bis Ethylenebenzthiazoline-6-sulfonic
acid, Sigma, USA) were added to each well. The reaction was
stopped after 4 min by adding 50 ml of 1% Sodium Dodecyl Sulfate.
Optical Density (OD) was read at 415 nm in a microplate reader
(Biorad, USA). The OD value for each serum was calculated by
subtracting the mean OD of wells coated with VLP from the OD of
wells coated with PBS. The cut points for seropositivity for HPV 16
and 18 were determined from the positive controls provided by
WHO [15].Results
Mean age of group A was 30.44 years, and most patients
reported having a college degree (66.7%) and being single (77.8%).
The average age of group B was 34, 50% reported having com-
pleted high school and 80% were single (these characteristics were
not different).
Six patients had anti-HPV antibodies before baseline and
therefore were excluded from further analysis. The remaining 19
HIV-infected patients and ﬁve controls had titers of anti-HPV
antibodies below the cut-off of 0.216. Four weeks after the
administration of the ﬁrst dose of vaccine an increase in titers of
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Fig. 1. : Anti-HPV serum titers from HIV-1-infected subjects and negative controls after vaccination with bivalent human papillomavirus vaccine (types 16 and 18).
A. Fontes et al. / Papillomavirus Research 2 (2016) 17–20 19circulating antibodies was detected. Three control subjects ser-
oconverted (60%), as well as ﬁve patients in group A (55.6%) and
three patients in group B (30%) as judged by increased antibody
titers measured by ELISA using VLP 16 HPV ranked by standard
titles (Fig. 1).
After the 2nd dose (at 30 days), four weeks after immunization,
there was an increase in titers of circulating antibodies in the
serum of patients. Four patients in the control group ser-
oconverted (80%), eight patients in group A (88.8%) and eight
patients in group B (80.0%) had increased titers of anti-HPV,
ranked by titles' standard. Finally, after the 3rd dose (at 180 days),
four weeks after immunization, there was an increase in circu-
lating antibodies in the serum of patients: ﬁve volunteers from the
control group (100%), eight HIV-infected patients from group A
(88.8%) and nine HIV-infected patients from group B (90%) ser-
oconverted (Fig. 1) after vaccination.Discussion
This study demonstrated that the bivalent HPV vaccine (Cer-
varix) was efﬁcacious when administered to HIV-infected-oral-
HPV- negative men, with more than 90 percent of patients pro-
ducing antibodies to HPV in high titers, after a full vaccination
scheme. It was also safe, with no major adverse effect reported.
The satisfactory response of HIV patients to the vaccine was
independent of their CD4 count, since both groups studied (CD4þ
T-cells count o500 and CD4þ T-cells count 4¼500 cells/mm3)
responded similarly to the vaccine, with approximately 90% of
seroconversion. Our results are in agreement with ﬁndings from
other authors [9], who also worked with HIV-infected men,
obtaining a 95% proportion of seroconversionwith a tetravalent
vaccine (2010) administered to sevento 12 years-old HIV-positive
children [13]. Our data strongly suggest that HPV vaccination
induces protective immunity against vaccine-speciﬁc HPV infec-
tion in persons with HIV [16]. Similarly, this efﬁcacy was found in
HIV-1-positive women from Africa [17].
The VLP-based bivalent vaccine administered to our patients did
not change their CD4þ counts or HIV viral loads. These ﬁndings were
also observed in two other studies involving immune depressed
patients [13,18]. Several factors may contribute to the nearly absence
of deleterious effects of the vaccine on the immune system, such as
the intrinsic immunogenicity of the VLPs, keeping an orderly and
repetitive arrangement of their epitopes, enabling a speciﬁc recogni-
tion by B cells. Another likely factor may be the characteristics of the
epitopes of the L1 region, which induce a broad neutralizing antibody
response, enabling the recognition of a certain type of HPV and its
variants through its amino acids sequences.
The high titers of antibodies induced by VLP may inhibit the
establishment of an infection through the occlusion of its bindingsites on the cell. VLP may also avoid the immunologic escape of
HPV, decreasing the expression of the capsid proteins, delaying the
production of virions until the cell differentiation is complete [19].
Patients did not report any serious adverse effect that could be
attributed to the vaccine, only minor complaints such as pain at
the injection site and headaches, considered mild or moderate and
similar to what has been observed for other vaccines when
administered to HIV-infected patients [9,18,20].
The efﬁcacy of the bivalent (16 and 18) HPV vaccine has been
demonstrated in several other studies, with consistent, compar-
able results for the two currently used vaccines. The long term
efﬁcacy of the vaccine is unknown, and follow-up studies are
currently been undertaken to examine whether a booster dose of
the vaccine will be needed in the future [21]. On a previous study
developed by our research team, Veiga et al. demonstrated that
the viral load from HIV carriers was the determinant factor for the
unsuccessful vaccination against hepatitis B [22]. Our results from
the current study are in agreement with two other studies which
found that the viral loads of HIV-1-infected patients, immunized
with Merck's tetravalent anti-HPV vaccine, were not associated
with their response to the vaccine.
Our study has some limitations such as the small number of
patients and controls, short follow-up time, precluding a better
comparison with the HIV negative population. We also did not
investigate the possibility of a cross-reaction of the vaccinethat
could protect the vaccinated against other HPV types not present
on the vaccine; another aspect not contemplated on our study was
the long term behavior of the antibodies’ titers in the patients sera.
We hope that our results help stimulate the HPV immunization of
the HIV-infected men, in order to decrease their risks of infection,
morbidity and mortality from HPV diseases, as well as averting the
risks of transmission.Author contributions
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